NVO Stock Overview
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide.
No risks detected for NVO from our risk checks.
Novo Nordisk A/S Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||kr.102.55|
|52 Week High||kr.122.16|
|52 Week Low||kr.91.51|
|1 Month Change||0.30%|
|3 Month Change||-7.81%|
|1 Year Change||5.79%|
|3 Year Change||97.48%|
|5 Year Change||108.39%|
|Change since IPO||20,513.11%|
Recent News & Updates
Novo Nordisk bolstered by another late-stage trial of once weekly insulin icodec
Results from the phase 3a ONWARDS 5 trial found that Novo Nordisk's (NVO) insulin icodec bested once-daily basal insulin in terms of lowering A1c. Data showed that insulin icodec led to a superior reduction in estimated A1c of –1.68%-points compared with –1.31%-points for the basal insulin. In the trial, insulin icodec was given in combination with a dosing guide app. There was no statistically significant difference in estimated rates of severe or clinically significant hypoglycemia Novo Nordisk (NVO) expects to apply for approval with regulatory authorities in US, the EU, and China in 1H 2023. Last month, the company reported results from the ONWARDS 2 trial that compared insulin icodec to Tresiba (insulin degludec).
Novo to buy sick cell disease drug developer Forma for over $1B
Danish drugmaker Novo Nordisk A/S (NVO) (OTCPK:NONOF) has agreed to acquire Forma Therapeutics (FMTX), a U.S.-based biotech focused on therapies for sickle cell disease (SCD), in an all-cash deal worth $1.1B in equity value, the companies announced Thursday. Per the terms, NVO will acquire all outstanding shares of FMTX’s common stock for $20 per share in cash, indicating a ~92% premium to the company’s 30-day volume-weighted average price per share. The transaction is expected to close in Q4 2022. In connection with the deal, R.A. Capital Management, L.P., which holds nearly ~19% of FMTX shares, has agreed to tender its FMTX shares in a tender offer that NVO plans to initiate for the acquisition. FMTX’s lead asset Etavopivat is undergoing a global phase 2/3 clinical trial for SCD and a phase 2 trial for transfusion-dependent SCD and thalassemia.
Novo Nordisk goes ex-dividend tomorrow
Novo Nordisk (NVO) declared $0.411/share dividend. Payable Aug. 23; for shareholders of record Aug. 15; ex-div Aug. 12. See NVO Dividend Scorecard, Yield Chart, & Dividend Growth.
|NVO||US Pharmaceuticals||US Market|
Return vs Industry: NVO exceeded the US Pharmaceuticals industry which returned 3.2% over the past year.
Return vs Market: NVO exceeded the US Market which returned -23.2% over the past year.
|NVO Average Weekly Movement||5.3%|
|Pharmaceuticals Industry Average Movement||11.2%|
|Market Average Movement||6.8%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: NVO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: NVO's weekly volatility (5%) has been stable over the past year.
About the Company
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases.
Novo Nordisk A/S Fundamentals Summary
|NVO fundamental statistics|
Is NVO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|NVO income statement (TTM)|
|Cost of Revenue||kr.25.29b|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Nov 02, 2022
|Earnings per share (EPS)||22.33|
|Net Profit Margin||32.14%|
How did NVO perform over the long term?See historical performance and comparison